OCT 11, 2016 08:00 AM PDT

Pro-Enkephalin: A Novel New Biomarker for Assessment of Kidney Function, Early Prediction and Identification of Acute Kidney Injury

SPONSORED BY: Sphingotec LLC, Sphingotec LLC
C.E. CREDITS: P.A.C.E. CE | Florida CE
  • Professor of Medicine , UC San Diego Director, Coronary Care Unit and Heart Failure Program, Veterans Affairs San Diego Healthcare System
      Dr. Maisel graduated from the University of Michigan Medical School, received his internal medicine training at Michael Reese Hospital in Chicago, and completed a cardiology fellowship at the University of California, San Diego.

      Dr. Maisel is a Professor of Medicine at the University of California, San Diego (UCSD). He is the Director of the Coronary Care Unit and Heart Failure Program at the VA San Diego Healthcare System in La Jolla, California. Dr. Maisel is active on the faculty at UCSD where he has won numerous teaching awards. He just finished a ten-year stint as Associate Editor of the Journal of the American College Cardiology.

      He is considered one of the world's experts on cardiac biomarkers and has over 300 scientific publications. He has authored several ground-breaking publications that have paved the way for development of diagnostic tools for patients with congestive heart failure. In particular, he was the leading investigator on studies that brought the use of BNP into clinical practice.

    DATE:  October 11, 2016
    TIME:  8:00am PT, 11:00 ET

    Chronic Renal Dysfunction (CKD) and Acute Kidney Injury (AKI) are increasing in prevalence today and can be escalated due to diseases such as diabetes, surgical procedures as well as nephrotoxic treatments.  Acute kidney injury (AKI) represents an acute decline in renal function that leads to structural changes. AKI is associated with increased mortality, length of hospital stay and costs .  This unfavorable outcome might be tied to the late detection of AKI when the elevation of serum creatinine (SCr) is used.  No currently available biomarkers have been demonstrated to meet clinical needs for prediction, diagnosis and management.  

    ProEnkephalin (PENK) is an endogenous opioid hormone that has been demonstrated to be released in proportion to increasing renal distress and dysfunction.  Blood levels of PENK have been assessed now in thousands of patients and in multiple studies of both CKD and AKI.  This data will be reviewed by Dr. Alan Maisel, a leader in the field of novel protein biomarkers.
    Learning Objectives: 
    • Characterize the clinical challenge of chronic and acute kidney injury (AKI) and the limitations for predicting, diagnosing and managing AKI
    • Review ProEnkephalin, its function and role as an endogenous opioid hormone, and its relationship to renal function
    • Review recently published data in European and North American cohorts examining ProEnkephalin levels in predicting outcomes in chronic renal function and acute kidney injury.

    Show Resources
    Loading Comments...